U.S. market Closed. Opens in 1 day 21 hours 47 minutes

PCRX | Pacira BioSciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 18.73 - 19.80
52 Week Range 11.16 - 35.95
Beta 0.80
Implied Volatility 87.04%
IV Rank 33.52%
Day's Volume 2,807,508
Average Volume 690,987
Shares Outstanding 46,173,200
Market Cap 876,367,336
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2011-02-03
Valuation
Profitability
Growth
Health
P/E Ratio -9.59
Forward P/E Ratio N/A
EPS -1.98
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 711
Country USA
Website PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
*Chart delayed
Analyzing fundamentals for PCRX we got that it has weak fundamentals where Valuation is considered to be undervalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see PCRX Fundamentals page.

Watching at PCRX technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on PCRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙